Sweden's Lumito Q4 net sales at zero, net loss narrows

Lumito AB (publ)

20/02/2026 07:40

Overview

Swedish medical tech firm's Q4 net sales were 0, compared to 79 KSEK last year

Q4 net income loss narrowed to 11,244 KSEK from net loss of 15,476 KSEK last year

Company's Q4 loss per share improved to -0.01 SEK from -0.06 SEK

Outlook

Lumito did not provide specific financial guidance for 2026 in its press release

Result Drivers

NO SALES - Lumito reported zero net sales for Q4 2025, compared to 79 KSEK in the same period last year, as the company transitions to a commercial phase

COST OPTIMIZATION - Decrease in personnel and external costs due to organizational optimization for the commercial phase, conversion to consultants, and cost-efficiency measures

DEPRECIATION INCREASE - Increased depreciation due to SCIZYS product completion in July 2024, leading to higher depreciation costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 0
Q4 Adjusted EPS
-SEK 0.01
Q4 Net Income
-SEK 11.24 mln
Q4 Adjusted Free Cash Flow
-SEK 8.62 mln


Press Release: ID:nMFN63SmKy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)